ODI Pharma AB (XSAT:ODI) Debt-to-Equity: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ODI ODI Pharma AB XSAT:ODI
48 GF Score
Price kr1.98
GF Value kr7.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is ODI Pharma AB Debt-to-Equity?

ODI Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr Mil. ODI Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr Mil. ODI Pharma AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr2.38 Mil. ODI Pharma AB's debt to equity for the quarter that ended in Jun. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ODI Pharma AB's Debt-to-Equity or its related term are showing as below:

XSAT:ODI's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

ODI Pharma AB  (XSAT:ODI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


ODI Pharma AB Debt-to-Equity Related Terms


ODI Pharma AB Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for ODI Pharma AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB Debt-to-Equity Chart

ODI Pharma AB Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Debt-to-Equity
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -

ODI Pharma AB Quarterly Data
Jun21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -

XSAT:ODI vs ZTS, UTHR: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ODI Pharma AB Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ODI Pharma AB's Debt-to-Equity falls into.


XSAT:ODI
48GF Score
ODI Pharma AB XSAT:ODI
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ODI Pharma AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ODI Pharma AB's Debt to Equity Ratio for the fiscal year that ended in Jun. 2026 is calculated as

ODI Pharma AB's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr1.98 is trading 72.2% below its estimated GF Value™ of kr7.12. GuruFocus considers ODI Pharma AB to be Possible Value Trap.

Key valuation signals for XSAT:ODI:

  • Debt-to-Equity:
  • GF Value™: kr7.12 vs. price of kr1.98 (72.2% below fair value)
  • GF Score™: 48/100 with 1 warning sign

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ODI Pharma AB Business Description

Address Ostermalmstorg 1, Stockholm, SWE, 114 42
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
48GF Score

Get the complete analysis for XSAT:ODI

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.98
Price
kr7.12
GF Value